Compare Inovio Pharmaceuticals Inc (INO) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Orion Office REIT Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Orion Office REIT Inc trades at $2.65 (market cap $150.60M). The key difference: Orion Office REIT Inc is the larger of the two by market cap, and Orion Office REIT Inc pays a 3.02% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | ONL | |
|---|---|---|
Market Cap | $89.27M | $150.60M |
Sector | Health | Real Estate |
52-Week High | $2.87 | $3.04 |
52-Week Low | $1.05 | $1.93 |
Enterprise Value | $60.28M | $634.25M |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
ONL trades at $2.65, up 0.76% today, with a bullish technical signal despite bearish moving averages. The company reported Q1 2026 earnings with a net loss of $0.24 per share, missing estimates, while revenue declined to $147.65 million in 2025. A strategic review is underway with Wells Fargo and JPMorgan, focusing on portfolio repositioning and debt management, as highlighted in recent earnings calls (MarketBeat, 2026-05-14).
Outlook remains challenging due to persistent losses and high leverage, but the strategic shift toward dedicated-use assets and resolved refinancing risks offer potential upside. Investors face significant execution and market headwinds, with analyst consensus split evenly between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
